Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Screening for medicine and food homologous ingredients targeting ALDH2 to alleviate acute ethanol-induced liver injury.

Created on 14 Oct 2026

Authors

Yuan Lu, Zibin Li, Pan Gao, Yushan Liu, Lin Han, Ji Bian, Min Wang

Published in

Frontiers in nutrition. Volume 13. Pages 1913449. Epub Sep 29, 2026.

Abstract

Alcoholic liver disease (ALD) is a major global health burden with limited therapeutic options. Aldehyde dehydrogenase 2 (ALDH2) plays a critical role in alcohol metabolism, and ALDH2 deficiency exacerbates alcohol-induced hepatic injury.
This study aimed to identify and validate natural ALDH2 activators from medicine and food homologous sources for alleviating acute ethanol-induced liver injury.
A literature-based screening revealed 18 candidate compounds. In vitro enzyme kinetics, molecular docking, and isothermal titration calorimetry were employed to identify four potent ALDH2 activators from these 18 candidates. The hepatoprotective effects of the four candidates were validated in vivo using serum biochemical analyses, oxidative stress measurements, and histopathological examinations in the Gao-binge ALD mouse model.
Puerarin, sophoricoside, quercetin, and daidzin were preliminarily identified as mixed-type ALDH2 activators, which increased the acetaldehyde dehydrogenation rate catalyzed by ALDH2. These compounds significantly improved motor coordination, reduced blood ethanol and acetaldehyde levels, attenuated hepatic steatosis, normalized transaminase activities, restored antioxidant capacity, and ameliorated liver histopathological damage in the mouse model.
Several natural ALDH2 activators from medicine and food homologous sources with potent hepatoprotective effects were identified, providing the scientific basis for developing healthy foods and dietary supplements to alleviate acute ethanol-induced liver injury.

PMID:
42871545
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement